MX2021002380A - Conjugados de isoquinolina-esteroide y usos de los mismos. - Google Patents

Conjugados de isoquinolina-esteroide y usos de los mismos.

Info

Publication number
MX2021002380A
MX2021002380A MX2021002380A MX2021002380A MX2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A
Authority
MX
Mexico
Prior art keywords
methods
compounds
isoquinoline
subject
kinase activity
Prior art date
Application number
MX2021002380A
Other languages
English (en)
Spanish (es)
Inventor
Mitchell A Delong
Eric Carlson
Jill M Sturdivant
Casey Kopczynski
Cynthia L Lichorowic
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of MX2021002380A publication Critical patent/MX2021002380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2021002380A 2018-08-31 2019-08-30 Conjugados de isoquinolina-esteroide y usos de los mismos. MX2021002380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725941P 2018-08-31 2018-08-31
PCT/US2019/049195 WO2020047496A1 (en) 2018-08-31 2019-08-30 Isoquinoline-steroid conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2021002380A true MX2021002380A (es) 2021-07-15

Family

ID=69639319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002380A MX2021002380A (es) 2018-08-31 2019-08-30 Conjugados de isoquinolina-esteroide y usos de los mismos.

Country Status (10)

Country Link
US (2) US11059789B2 (enExample)
EP (1) EP3843736A4 (enExample)
JP (1) JP7437384B2 (enExample)
KR (1) KR20210053301A (enExample)
CN (1) CN112638386A (enExample)
AU (2) AU2019328590B2 (enExample)
BR (1) BR112021003613A2 (enExample)
MX (1) MX2021002380A (enExample)
SG (1) SG11202101517PA (enExample)
WO (1) WO2020047496A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7437384B2 (ja) 2018-08-31 2024-02-22 アエリエ ファーマシューティカルズ インコーポレイテッド イソキノリンステロイド抱合体およびその使用
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
CN117561270A (zh) * 2021-04-29 2024-02-13 爱瑞制药公司 稳定的异喹啉-皮质类固醇缀合物及其用途
US20250057962A1 (en) * 2021-11-03 2025-02-20 Ripple Therapeutics Corporation Processable compositions and use for the same
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3193459A (en) 1955-07-01 1965-07-06 Upjohn Co Steroid hemisuccinate compositions and method for extemporaneous administration
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US20100041633A1 (en) * 2007-02-05 2010-02-18 Nicox S.A. Nitric oxide releasing steroids
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) * 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9402912B2 (en) * 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
CN105025929A (zh) 2013-03-08 2015-11-04 阿勒根公司 环孢菌素a-类固醇缀合物
US20140275160A1 (en) * 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
BR112019003232A2 (pt) * 2016-08-19 2019-06-18 Aerie Pharmaceuticals Inc compostos de beta-amino-isoquinolinil amida, composições que o incluem e métodos de obtenção
JP7437384B2 (ja) 2018-08-31 2024-02-22 アエリエ ファーマシューティカルズ インコーポレイテッド イソキノリンステロイド抱合体およびその使用

Also Published As

Publication number Publication date
EP3843736A1 (en) 2021-07-07
US20210300874A1 (en) 2021-09-30
JP2021535147A (ja) 2021-12-16
WO2020047496A1 (en) 2020-03-05
AU2019328590B2 (en) 2023-04-13
KR20210053301A (ko) 2021-05-11
AU2019328590A1 (en) 2021-03-11
AU2023204624A1 (en) 2023-08-03
CN112638386A (zh) 2021-04-09
US20200071275A1 (en) 2020-03-05
BR112021003613A2 (pt) 2021-05-18
US11691950B2 (en) 2023-07-04
SG11202101517PA (en) 2021-03-30
JP7437384B2 (ja) 2024-02-22
US11059789B2 (en) 2021-07-13
EP3843736A4 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2020010369A (es) Particulas implantables y metodos relacionados.
MY197845A (en) Pharmaceutical composition
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
EP4445954A3 (en) Cellular models of and therapies for ocular diseases
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
NZ737471A (en) Hydrophilic linkers for conjugation
WO2014143754A3 (en) Prostamide-containing intraocular implant
WO2016060564A8 (en) Body sculpting
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
WO2017156495A8 (en) Compounds and methods for modulating bruton's tyrosine kinase
NZ746468A (en) Methods of treating ocular conditions
EP4410312A3 (en) Topical cyclosporine-containing formulations and uses thereof
WO2019241672A3 (en) Glycosylated comp pilin variants, methods of making and uses thereof
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2017142895A8 (en) Compositions and methods for treating clostridium associated diseases